학술논문
Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron.
Document Type
Article
Author
Source
Clinical Pharmacology & Therapeutics; Aug2017, Vol. 102 Issue 2, p213-218, 6p
Subject
Language
ISSN
00099236
Abstract
The article focuses on a guideline issued by the Clinical Pharmacogenetics Implementation Consortium (CPIC) for CYP2D6 Genotype and use of Ondansetron and Tropisetron. It mentions that CYP2D6 is highly polymorphic with over 100 known allelic variants and subvariants. It further mentions that Ondansetron is metabolized to four inactive metabolites by multiple CYP enzymes.